5-(叔丁基二甲基硅氧基)-1H-吲哚 | 106792-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-(叔丁基二甲基硅氧基)-1H-吲哚
• 中文别名: 5-(叔丁基二甲基甲硅烷基氧基)-1H-吲哚
• 英文名称: 5-((tert-butyldimethylsilyl)oxy)-1H-indole
• 英文别名: 5-(tert-butyl-dimethyl-silanyloxy)-1H-indole；5-(tert-Butyldimethylsilyloxy)-1H-indole；tert-butyl-(1H-indol-5-yloxy)-dimethylsilane
• CAS: 106792-38-5
• 化学式: C₁₄H₂₁NOSi
• 分子量: 247.412
• InChiKey: LUUANNCTVICLCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  60-62

计算性质

• 辛醇/水分配系数(LogP)：
  4.55
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(tert-Butyldimethylsilyloxy)-1H-indole
Synonyms: 5-TBDMSO-1H-indole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(tert-Butyldimethylsilyloxy)-1H-indole
CAS number: 106792-38-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H21NOSi
Molecular weight: 247.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(叔丁基二甲基硅氧基)-1H-吲哚 在 盐酸 、 甲醇 、 水 、 双氧水 、 sodium hydride 、 potassium carbonate 、 溶剂黄146 、 丙酸 、 三乙胺 、 potassium hydroxide 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 44.67h， 生成 2-acetylamino-3-{4-[5-methoxy-1-(toluene-4-sulfonyl)-1H-indole-3-carbonyl]-5-methoxy-1H-indol-3-yl}-propionic acid
  参考文献：
  名称：

  Total synthesis of (±)-hyrtiazepine

  摘要：

  The total synthesis of the azepinoindole alkaloid, (+/-)-hyrtiazepine, was achieved. Construction of the azepinoindole core structure was carried out by C-4 selective alpha-hydroxyalkylation of 5-hydroxyindole, introduction of serine at C-3 of the indole moiety, and intramolecular imination. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2011.01.029
• 作为产物：
  描述：

  5-羟基吲哚 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以100%的产率得到5-(叔丁基二甲基硅氧基)-1H-吲哚
  参考文献：
  名称：

  发现一类新型的有效和选择性非竞争性Sentrin特异性蛋白酶1抑制剂。

  摘要：

  Sentrin特异性蛋白酶（SENP）负责小的泛素样修饰剂（SUMO）的成熟以及SUMO从其底物蛋白的脱结合。对前列腺癌的研究表明SENP1的过表达，可促进前列腺癌的进展以及转移。因此，SENP1已被确定为针对前列腺癌的新型药物靶标。在这里，我们报告了有效的和选择性的SENP1抑制剂的发现和生物学评估。新发现的吡啶酮支架的构效关系（SAR）显示出变构抑制剂具有极具吸引力的体外ADMET特性，涉及该挑战目标的血浆结合和血浆稳定性。该研究还强调了从头设计抑制剂的生化抑制研究模式的重要性。

  DOI：

  10.1002/cmdc.202000067
• 作为试剂：
  描述：

  咪唑 、 5-羟基吲哚 、 叔丁基二甲基氯硅烷 在 乙酸乙酯 、 水 、 magnesium sulfate 、 二氯甲烷 、 hexanes 、 5-(叔丁基二甲基硅氧基)-1H-吲哚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以60% dichloromethane in hexanes) to give 5-(tert-butyl-dimethyl-silanyloxy)-1H-indole (intermediate B) as a colorless oil which的产率得到5-(叔丁基二甲基硅氧基)-1H-吲哚
  参考文献：
  名称：

  Method of treating cancer

  摘要：

  本发明涉及使用一种PSA结合物和一种抑制血管生成的化合物的组合治疗癌症的方法，该方法包括向哺乳动物施用至少两种治疗剂量，这些治疗剂量从以下组合中选择：一种PSA结合物和一种抑制血管生成的化合物。该发明还涉及制备这种组合物的方法。

  公开号：

  US20020041880A1

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents
  申请人：Ackermann Jean

  公开号：US20050096353A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula wherein one of R 6 , R 7 and R 8 is and X, Y 1 to Y 4 , R 1 to R 14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

  这项发明涉及以下式的化合物 其中R 6 、R 7 和R 8 中的一个是 和X、Y 1 至Y 4 、R 1 至R 14 和n如描述中所定义的，并且所有的对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病。
• [EN] INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS<br/>[FR] DERIVES D'INDOLYLE PYRAZINONE UTILES POUR LE TRAITEMENT DES MALADIES ET DES TROUBLES HYPERPROLIFERANTS ASSOCIES A L'ANGIOGENESE
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004043950A1

  公开（公告）日：2004-05-27

  This invention relates to a compound of Formula I (I)and its use in treating hyper-proliferative disorders and diseases associated with angiogenesis.

  这项发明涉及一种式I（I）化合物及其在治疗与血管生成有关的高增殖性疾病和疾病中的应用。
• Csp²–N Bond Formation via Ligand-Free Pd-Catalyzed Oxidative Coupling Reaction of <i>N</i>-Tosylhydrazones and Indole Derivatives
  作者：Maxime Roche、Gilles Frison、Jean-Daniel Brion、Olivier Provot、Abdallah Hamze、Mouad Alami

  DOI：10.1021/jo401217x

  日期：2013.9.6

  system was found to promote the Csp2–N bond-forming reaction utilizing N-tosylhydrazones and N-H azoles. This process shows functional group tolerance; di-, tri-, and tetrasubstituted N-vinylazoles were obtained in high yields. Under the optimized conditions, the reaction proceeds with high stereoselectivity depending on the nature of the coupling partners.

  在一种新的合成N-乙烯基唑的方法中，发现无配体的钯催化体系可利用N-甲苯磺酰hydr和NH唑类促进Csp 2 -N键形成反应。此过程显示了功能组的容忍度；高产率地获得了二，三和四取代的N-乙烯基唑。在最佳条件下，取决于偶合体的性质，反应以高的立体选择性进行。
• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。